polyvalent vaccine-KLH conjugate
/ MabVax
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 28, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
(PubMed, Gynecol Oncol)
- P2; "Vaccine + OPT-821 compared to OPT-821 alone was modestly immunogenic and did not prolong PFS or OS. Multi-remission patients are a viable, well-defined population for exploring innovative consolidation and maintenance approaches."
Clinical • Journal • P2 data
1 to 1
Of
1
Go to page
1